Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment - PowerPoint PPT Presentation

ostinmannual
critical success factors for the korean generic and api industry in a post fta environment n.
Skip this Video
Loading SlideShow in 5 Seconds..
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment PowerPoint Presentation
Download Presentation
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment

play fullscreen
1 / 20
Download Presentation
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment
594 Views
Download Presentation

Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007

  2. AGENDA • About Thomson Reuters • Possible effect of KORUS Free Trade Agreement on Korean generic and API industries • The role of information in generic product development • Horizon Global™: an industry standard for generic product selection

  3. ABOUT API INTELLIGENCE (fmr Newport Strategies) • Founded in 1990 • A business of the $7bn Thomson Reuters Corporation • A unique research focus: tracking global generic API development and manufacturing activities • High quality, “must have” information delivery to executives in • Strategy, Planning and Product Targeting • Business Development & Licensing • Competitive & Business Intelligence • R&D and Regulatory Affairs • API Sourcing • Patents & Intellectual Property • Relied upon by the majority of the world’s generic pharmaceutical companies and API manufacturers • Headquartered in Portland, Maine, USA

  4. GENERICS: A $90B GLOBAL OPPORTUNITY Western Europe $17bn Eastern Europe & Russia: $10bn China: $3bn US, Canada: $50bn Japan: $4bn Rest of World: $4bn Latin America: $2bn Total World Pharmaceutical Sales: $600bn Source: TS Research, IMS Health, VOI PharmaHandbook

  5. KOREA & THE KORUS FREE TRADE AGREEMENT • Korean drug industry was $7.8 billion in 2005 of which generic drugs accounted for 15% of the market¹ • Korean population is aging more rapidly than any other country with healthcare spending by those over 65 years old growing by 10% to 20% annually¹ • KORUS FTA includes commitments to improve access of US innovative and generic pharmaceutical products to South Korean market² • As of 2005, foreign company share of the Korean market was at 26%¹ Source: ¹ VOI PharmaHandbook 2006,IMS Health; ²www.ustr.gov Trade Facts

  6. HOW COULD THE FTA IMPACT KOREAN GENERICS & API COMPANIES • It will drive more branded sales as generics will see increased barriers to entry in Korean market • It will increase foreign company share of Korean market • It will provide enhanced access to the US market for Korean API and dose outsourcing supply • It will have negative impact on Korean companies (both dose and API) given Indian and Chinese competition • It will increase competition for domestic company share of Korean market Korea has the expertise to compete in other regulated markets and should look to US and EU supply opportunities for growth!

  7. WHAT CHALLENGES WILL KOREAN GENERIC & API COMPANIES FACE IN THIS NEW ENVIRONMENT? • India is excellent at low-cost, high quality finished dose products • China is known for low-cost, high quality API and intermediates • In- and out-licensing will be as important as domestic in-house product development • A number of products worldwide coming off patent with a growing number of competing generic companies • Early access to API is still the key to speed to market and success

  8. AVAILABILITY OF HIGH-QUALITY API IN INDIA, CHINA & KOREA Source: Newport Strategies Horizon Global ™

  9. US DMF FILINGS BY INDIAN, CHINESE & KOREAN API MANUFACTURERS Source: Newport Strategies Horizon Global ™

  10. COS FILINGS BY INDIAN, CHINESE & KOREAN API MANUFACTURERS

  11. TYPE I JAPANESE DMF FILINGS BY INDIA, CHINESE & KOREAN API MANUFACTURERES, 2005-2007 Source: Newport Strategies Horizon Global ™

  12. NUMBER OF API PLANTS INSPECTED BY THE US FDA SINCE 1990 IN INDIA, CHINA & SOUTH KOREA Source: Newport Strategies Horizon Global ™

  13. ANDA APPROVALS BY INDIAN GENERICS Source: Newport Strategies Horizon Global ™

  14. GENERIC DRUG & API MANUFACTURERES HAVE MANY QUESTIONS… What is the patent or exclusivity situation? Who is competing with us? What should I develop? Where do I source the API? How big is the market? Do I partner or develop alone? Should I focus on regulated markets? Where should I launch?

  15. THE GENERIC PRODUCT DEVELOPMENT PROCESS Targeting Evaluation Deal Making Formulation Dev’t Registration & Review Launch L – 18 months Launch L – 8 years L – 7 years L – 6 years Target possible candidates for development Research product candidates in detail Find the right partners Make products quickly and safely Get first approval Deliver to the customer!

  16. THE ROLE OF INFORMATION IN THE GENERIC PROCESS Targeting Evaluation Deal Making Formulation Dev’t Registration & Review Launch Information Needs - Data • Sales* • Dose Form and Strength* • Patents, Patent Challenges* • Labeling • Chemistry, Synthesis • Data Exclusivity* • Market Exclusivity* • Approvals • API Sources* • Company Data* • Manufacturing Capabilities* • Bioequivalence • Stability • Pharmacodynamics • Toxicity • Country Regulations* • Pack Pricing* • Reimbursement *Available from Thomson Scientific

  17. KEY BUSINESS NEEDS IN THE GENERIC PROCESS Targeting Evaluation Deal Making Formulation Dev’t Registration & Review Launch Business Needs - Functionality • Access global market, intellectual property and product info* • Predict key data in advance (e.g. competitiveness, generic launch date)* • Flexible, fast searching across multiple, exacting criteria* • Identify early, viable source of API supply and backup sources* • Spot in- and out-licensing capabilities* • Identify potential partner companies with multiple, exacting criteria* • Keep a watchful eye on potential acquisition targets, track competitors* *Available from Thomson Scientific

  18. HORIZONS GLOBAL: A GENERIC INDUSTRY STANDARD • First launched in December 2002 • Version 3.5 released December 2006 • Version 4.0 targeted for summer 2007 • Used by at least 3 of the top 5 companies in every generic market • 100+ companies • 2,500+ users • Used by companies to strategically target products for development, find partners, and attract customers

  19. HORIZONS GLOBAL: A GENERIC INDUSTRY STANDARD (cont) • Designed to meet key generic business needs: • Target products and companies • Evaluate products and companies • Find early API sources • Identify licensing opportunities • Track competitive developments • Searchable content includes: • 10,000 launched APIs • 18,000 corporate groups and 3,500 API manufacturing sites • 92 patent countries • Incorporates unique intelligence and analysis on API development

  20. Please Come and Visit Us at our Booth • David Harding • Newport Sales Support Specialist • Thomson Reuters 215 Commercial Street • Portland, Maine 04101 • USA • + 1 (207) 871-9700 x27 • david.harding@thomsonreuters.com James Noh Sales Manager Thomson Reuters Asia Pacific Tel :+82 2 2076 8101 Fax:+82 2 2076 8122 Mobile:+82 18 210 6522 Email: james.noh@thomson.reuters.com